Published on February 18, 2025, in the Journal of Hepatology, the NuTide:121 study investigated NUC-1031/cisplatin as a first-line treatment for advanced biliary tract cancer (aBTC) compared to the gemcitabine/cisplatin standard of care.
The trial, one of the largest in first-line aBTC, was terminated early due to futility, as overall survival (OS) and progression-free survival (PFS) favored gemcitabine/cisplatin. While NUC-1031/cisplatin showed a higher objective response rate (18.7% vs. 12.4%), the OS was lower (9.2 vs. 12.6 months). The study also reported more liver-related adverse events with NUC-1031 but fewer hematological toxicities.
These findings confirm gemcitabine/cisplatin remains the first-line standard for aBTC, and efforts must continue to explore better therapeutic options.
A special thanks to all the researchers involved for their dedication to advancing cancer treatment.
For more info, check out the full study: https://lnkd.in/ebghTa9A
